Focused On-demand Library for Protein AMBP

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
P02760

UPID:
AMBP_HUMAN

ALTERNATIVE NAMES:
Protein HC

ALTERNATIVE UPACC:
P02760; P00977; P02759; P78491; Q2TU33; Q5TBD7; Q9UC58; Q9UDI8

BACKGROUND:
Protein AMBP functions as a Kunitz-type serine protease inhibitor, playing a pivotal role in extracellular space remodeling and cell adhesion. It inhibits several proteases involved in inflammation and coagulation, contributing to the regulation of extracellular matrix structure and function. Its activity in the extracellular matrix surrounding the oocyte is vital for ovulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted role of Protein AMBP offers promising avenues for therapeutic intervention. Its protease inhibitory function, particularly in the context of inflammation and coagulation, highlights its potential as a therapeutic target in diseases characterized by excessive inflammation and abnormal coagulation.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 7740 of 8789